Skip to content

Clinical trials

Completed Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Status: Completed Country / region: Canada Clear all

112 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20013
20026
20033
20044
20057
20067
20079
20085
20096
20103
20116
20124
20137
20142
20157
20175
20181
20192
20202
20211
20224
20231
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed112

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Children's Oncology Group35
National Cancer Institute (NCI)12
Novartis Pharmaceuticals6
Bristol-Myers Squibb4
Therapeutic Advances in Childhood Leukemia Consortium4
University of Alberta4
Dana-Farber Cancer Institute3
Jazz Pharmaceuticals3
Kiadis Pharma3
NCIC Clinical Trials Group3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma112
Leukemia40
Burkitt Lymphoma21
Leukemia, Myeloid, Acute20
Recurrence18
Leukemia, Lymphocytic, Chronic, B-Cell16
Lymphoma15
Lymphoma, Non-Hodgkin15
Blast Crisis13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive13

Trials

Showing 1 to 25 of 112. Each trial links to its page on Pharma Observatory.

12 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.